Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 91
- Registration Number
- NCT03687515
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT03677141
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of California; Moores Cancer Center, La Jolla, California, United States
Immunosuppressant Regimens for Living Fetuses Study
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 420
- Registration Number
- NCT03671174
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Cook County Health
- Target Recruit Count
- 10
- Registration Number
- NCT03661684
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 10
- Registration Number
- NCT03649841
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03625219
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 114
- Registration Number
- NCT03617432
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 12
- Registration Number
- NCT03613428
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 83
- Registration Number
- NCT03600805
- Locations
- 🇵🇹
Investigational Site Number 6200001, Almada, Portugal
🇩🇰Investigational Site Number 2080002, Aarhus C, Denmark
🇫🇷Investigational Site Number 2500006, Pessac, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath